F Lerebours

Summary

Country: France

Publications

  1. pmc NF-kappa B genes have a major role in inflammatory breast cancer
    Florence Lerebours
    Centre Rene Huguenin, FNCLCC, 35 rue Dailly, 92210, St Cloud, France
    BMC Cancer 8:41. 2008
  2. ncbi Evidence of chromosome regions and gene involvement in inflammatory breast cancer
    Florence Lerebours
    Inserm E0017 oncogénétique, St Cloud, France
    Int J Cancer 102:618-22. 2002
  3. ncbi [Primary systemic therapy in breast cancer: clinical and molecular factors predictors of outcome and response]
    F Lerebours
    Inserm E0017 oncogénétique, Saint Cloud, France
    Pathol Biol (Paris) 54:209-14. 2006
  4. pmc Update on inflammatory breast cancer
    Florence Lerebours
    Inserm E0017 oncogénétique, Centre Rene Huguenin, St Cloud, France
    Breast Cancer Res 7:52-8. 2005
  5. ncbi Two prognostic groups of inflammatory breast cancer have distinct genotypes
    Florence Lerebours
    Institut National de la Santé et de la Recherche Médicale INSERM E0017 Oncogénétique, Centre Rene Huguenin, 35 rue Dailly, F 92211 St Cloud, France
    Clin Cancer Res 9:4184-9. 2003
  6. ncbi ERBB2 status and benefit from adjuvant tamoxifen in ERalpha-positive postmenopausal breast carcinoma
    I Bieche
    Laboratoire d oncogénétique, INSERM E0017, 35 rue Dailly, F 92211 St Cloud, France
    Cancer Lett 174:173-8. 2001
  7. ncbi Molecular alterations in sporadic breast cancer
    F Lerebours
    E0017 INSERM Oncogénétique, Centre Rene Huguenin, 35 rue Dailly, F 92211, St Cloud, France
    Crit Rev Oncol Hematol 44:121-41. 2002
  8. ncbi Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature
    Ivan Bieche
    Laboratoire d Oncogénétique INSERM E0017, Centre Rene Huguenin, St Cloud, France
    Clin Cancer Res 10:6789-95. 2004
  9. doi 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer
    Jean Louis Alberini
    Nuclear Medicine Department, Cancer Research Center Rene Huguenin, Saint Cloud, France
    Cancer 115:5038-47. 2009
  10. ncbi Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen
    Igor Girault
    Laboratoire d oncogénétique, Institut National de la Santé et de la Recherche Médicale E0017, Centre Rene Huguenin, F 92211 St Cloud, France
    Clin Cancer Res 9:1259-66. 2003

Collaborators

Detail Information

Publications14

  1. pmc NF-kappa B genes have a major role in inflammatory breast cancer
    Florence Lerebours
    Centre Rene Huguenin, FNCLCC, 35 rue Dailly, 92210, St Cloud, France
    BMC Cancer 8:41. 2008
    ..Given the role of NF-kappaB-related genes in cell proliferation, invasiveness, angiogenesis and inflammation, we postulated that they might be deregulated in IBC...
  2. ncbi Evidence of chromosome regions and gene involvement in inflammatory breast cancer
    Florence Lerebours
    Inserm E0017 oncogénétique, St Cloud, France
    Int J Cancer 102:618-22. 2002
    ..In contrast, the DNA amplification levels of ERBB2, MYC and CCND1, as measured by real-time quantitative PCR, did not differ between IBC and non IBC...
  3. ncbi [Primary systemic therapy in breast cancer: clinical and molecular factors predictors of outcome and response]
    F Lerebours
    Inserm E0017 oncogénétique, Saint Cloud, France
    Pathol Biol (Paris) 54:209-14. 2006
    ..New technologies like DNA microarrays are likely to provide in a next future surrogate markers of response to PST in Breast Cancer...
  4. pmc Update on inflammatory breast cancer
    Florence Lerebours
    Inserm E0017 oncogénétique, Centre Rene Huguenin, St Cloud, France
    Breast Cancer Res 7:52-8. 2005
    ..A more comprehensive view will probably be obtained by pan-genomic analysis of human IBC samples, and by functional in vitro and in vivo assays. These approaches may offer better patient outcome in the near future...
  5. ncbi Two prognostic groups of inflammatory breast cancer have distinct genotypes
    Florence Lerebours
    Institut National de la Santé et de la Recherche Médicale INSERM E0017 Oncogénétique, Centre Rene Huguenin, 35 rue Dailly, F 92211 St Cloud, France
    Clin Cancer Res 9:4184-9. 2003
    ..Analysis of loss of heterozygosity (LOH) can provide a molecular portrait of the genetic alterations underlying stepwise cancer progression. We tested the value of LOH patterns as diagnostic and prognostic markers in IBC...
  6. ncbi ERBB2 status and benefit from adjuvant tamoxifen in ERalpha-positive postmenopausal breast carcinoma
    I Bieche
    Laboratoire d oncogénétique, INSERM E0017, 35 rue Dailly, F 92211 St Cloud, France
    Cancer Lett 174:173-8. 2001
    ..00036). The results point to the need for a quantitative ERBB2 expression assay for use in future studies of ERBB2-based clinical management of breast cancer...
  7. ncbi Molecular alterations in sporadic breast cancer
    F Lerebours
    E0017 INSERM Oncogénétique, Centre Rene Huguenin, 35 rue Dailly, F 92211, St Cloud, France
    Crit Rev Oncol Hematol 44:121-41. 2002
    ....
  8. ncbi Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature
    Ivan Bieche
    Laboratoire d Oncogénétique INSERM E0017, Centre Rene Huguenin, St Cloud, France
    Clin Cancer Res 10:6789-95. 2004
    ..Inflammatory breast cancer (IBC) is a rare but particularly aggressive form of primary breast cancer. The molecular mechanisms responsible for IBC are largely unknown...
  9. doi 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer
    Jean Louis Alberini
    Nuclear Medicine Department, Cancer Research Center Rene Huguenin, Saint Cloud, France
    Cancer 115:5038-47. 2009
    ..To prospectively assess fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) staging and prognosis value in patients with suspected inflammatory breast cancer (IBC)...
  10. ncbi Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen
    Igor Girault
    Laboratoire d oncogénétique, Institut National de la Santé et de la Recherche Médicale E0017, Centre Rene Huguenin, F 92211 St Cloud, France
    Clin Cancer Res 9:1259-66. 2003
    ..Therefore, expression analysis of these ERalpha coregulators may identify new predictors of the response to tamoxifen treatment...
  11. ncbi Real-time reverse transcription PCR assay of CYP19 expression: application to a well-defined series of post-menopausal breast carcinomas
    I Girault
    Laboratoire d oncogénétique, INSERM E0017, Centre Rene Huguenin, 35 rue Dailly, St Cloud, F 92211 Paris, France
    J Steroid Biochem Mol Biol 82:323-32. 2002
    ..018). In conclusion, CYP19 expression did not influence the outcome of post-menopausal patients with breast cancer...
  12. doi Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy
    Romuald Le Scodan
    Department of Radiation Oncology, Centre Rene Huguenin, 35 rue Dailly, 92210, Saint Cloud, France
    J Clin Oncol 27:1375-81. 2009
    ..Exclusive locoregional radiotherapy (LRR) is an alternative form of locoregional treatment (LRT) in this setting. We retrospectively studied the impact of LRT on the survival of breast cancer patients with synchronous metastases...
  13. ncbi Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer
    Philippe Bertheau
    Service de Pathologie, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris, France
    Oncol Rep 14:513-20. 2005
    ..In conclusion, in 108 stage IIB to IIIB breast cancer patients initially treated by high-dose chemotherapy, combined grading of clinical and pathologic responses in a single score allowed accurate prediction of outcome...
  14. ncbi Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer
    Elizabeth Turpin
    Service de Biochimie B and CNRS UPR9051, Hopital Saint Louis, 1, avenue Claude Vellefaux, F 75475 Paris Cedex 10, France
    Oncogene 21:7593-7. 2002
    ..Given the importance of TP53 and ERBB2 in the response to treatments, our observations have important therapeutic implications for the clinical management of IBC patients...